13F Holdings
中文EN

RDY DR REDDYS LABORATORIES LTD IFRS Annual reports only

Pharmaceutical Preparations · NYSE · SEC CIK 1135951 · Reporting currency INR · Fiscal year ends 03/31

Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY16.6%
TTM net income YoY1.5%
TTM EPS YoY1.5%
Revenue 3-yr CAGR14.9%
Net income 3-yr CAGR33.9%

Margins

Gross margin58.5%
Operating margin22.1%
Net margin17.4%
FCF margin5.8%
EBITDA margin27.3%

Returns

ROE18.4%
ROA12.8%
ROIC (approx.)16.3%
Asset turnover0.74x

Leverage & solvency

Liabilities / assets31.6%
Debt / equity0.14x
Current ratio1.92x
Interest coverage25.40x

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio2.3%
Payout ratio11.8%
Capex / revenue8.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: INR FY20252025-03-31FY20242024-03-31FY20232023-03-31FY2022*2022-03-31FY2021*2021-03-31
Income statement
Revenue325.54B279.16B245.88B214.39B189.72B
Cost of revenue135.11B115.56B106.54B100.55B86.64B
Gross profit190.43B163.61B139.34B113.84B103.08B
R&D expense27.38B22.87B19.38B17.48B16.54B
SG&A expense93.87B77.20B68.03B62.08B54.65B
Operating income71.84B67.73B57.14B29.48B24.28B
Interest expense2.83B1.71B1.43B958.00M970.00M
Pretax income76.78B71.87B60.37B32.30B26.41B
Income tax19.54B16.19B15.30B8.73B9.18B
Net income56.54B55.68B45.07B23.57B17.24B
EBITDA88.90B82.57B69.78B41.30B37.08B
EPS (basic)67.8866.9354.28142.08103.94
EPS (diluted)67.7866.8054.17141.69103.65
Dividends declared per share40.0040.0030.0025.0025.00
Weighted avg. shares (diluted)834.18M833.54M831.94M166.34M166.32M
Banking
Net interest income-152.00M567.00M-248.00M7.00M-144.00M
Balance sheet
Cash & equivalents14.65B7.11B5.78B14.85B14.83B
Short-term investments43.25B74.36B56.02B29.51B19.74B
Receivables90.42B80.30B72.48B66.76B49.64B
Inventory71.08B63.55B48.67B50.88B45.41B
Current assets250.11B248.05B204.25B181.86B148.25B
PP&E, netmay include right-of-use assets (IFRS)97.76B76.89B66.46B62.17B57.11B
Goodwill11.81B4.25B4.25B4.42B4.57B
Intangibles96.80B36.95B30.85B27.25B35.65B
Total assets492.99B387.52B321.85B292.83B265.49B
Current liabilities130.39B96.04B85.84B94.02B83.39B
Short-term debt38.05B12.72B7.39B27.08B23.14B
Long-term debt7.86B5.99B1.28B5.75B6.30B
Total debt45.91B18.71B8.67B32.83B29.43B
Total liabilities155.82B106.97B90.86B102.30B92.43B
Shareholders' equity333.39B280.55B230.99B190.53B173.06B
Net debt31.25B11.61B2.89B17.98B14.61B
Shares outstanding832.64M830.78M829.79M165.73M165.78M
Cash flow statement
Operating cash flow46.43B45.43B58.88B28.11B35.70B
Capital expenditure27.50B16.40B11.32B14.66B9.74B
Free cash flow18.92B29.03B47.55B13.45B25.96B
Investing cash flow-58.08B-40.28B-41.37B-26.39B-22.66B
Financing cash flow18.91B-3.76B-26.86B-2.42B-298.00M
Depreciation & amortization17.06B14.84B12.64B11.82B12.80B
Stock-based compensation424.00M407.00M397.00M592.00M584.00M
Dividends paid6.66B6.65B4.98B4.15B4.15B
Share buybacks———01.19B

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, INR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.